Donald Notman

Director of Finance/CFO at OCULAR THERAPEUTIX, INC.

Net worth: 328 289 $ as of 30/04/2024

64 year

34 connections

Health Technology

Consumer Services

Finance

Active connections

Name	Gender	Age	Linked companies	Collaboration
Charles Warden	M	55	OCULAR THERAPEUTIX, INC.	16 years
Scott Corning	M	-	OCULAR THERAPEUTIX, INC.	14 years
Jeffrey S. Heier	M	63	OCULAR THERAPEUTIX, INC.	9 years
Richard Lindstrom	M	76	OCULAR THERAPEUTIX, INC.	12 years
Merilee Raines	F	68	OCULAR THERAPEUTIX, INC.	3 years
Leslie Williams	F	64	OCULAR THERAPEUTIX, INC.	5 years
Seung Suh Hong	M	66	OCULAR THERAPEUTIX, INC.	5 years
Adrienne Graves	M	69	OCULAR THERAPEUTIX, INC.	1 years
Pauline Jen Ryan	F	-	OCULAR THERAPEUTIX, INC.	-
Peter Jarrett	M	-	OCULAR THERAPEUTIX, INC.	17 years
Christopher White	M	62	OCULAR THERAPEUTIX, INC.	5 years
Philip Strassburger	M	64	OCULAR THERAPEUTIX, INC.	4 years
Peter K. Kaiser	M	-	OCULAR THERAPEUTIX, INC.	-
Pravin Dugel	M	60	OCULAR THERAPEUTIX, INC.	-
Tracy Smith	F	-	OCULAR THERAPEUTIX, INC.	4 years
Karen-Leigh Edwards	M	-	OCULAR THERAPEUTIX, INC.	3 years

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Amarpreet S. Sawhney	M	57	OCULAR THERAPEUTIX, INC.	13 years
Antony Mattessich	M	57	OCULAR THERAPEUTIX, INC.	7 years
Jim O'Shea	M	74	OCULAR THERAPEUTIX, INC.	4 years
Bruce Peacock	M	72	OCULAR THERAPEUTIX, INC.	8 years
Joseph Zakrzewski	M	60	Thrasos Therapeutics, Inc. Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada.	-
George Migausky	M	69	OCULAR THERAPEUTIX, INC.	-
Kevin Hanley	M	62	OCULAR THERAPEUTIX, INC.	2 years
Patricia Kitchen	F	46	OCULAR THERAPEUTIX, INC.	2 years
Chad Brines	M	-	OCULAR THERAPEUTIX, INC.	4 years
Jonathan M. Sparks	M	-	OCULAR THERAPEUTIX, INC.	-
Nicole Carta	F	-	OCULAR THERAPEUTIX, INC.	-
Naymisha Patel	F	-	OCULAR THERAPEUTIX, INC.	-
Rabia Ozden	M	56	OCULAR THERAPEUTIX, INC.	3 years
Daniel M. Bollag	M	63	OCULAR THERAPEUTIX, INC.	2 years
Michael H. Goldstein	M	57	OCULAR THERAPEUTIX, INC.	-
Gaétan Gravel	M	-	Thrasos Therapeutics, Inc. Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada.	-
Jaswinder S. Chadha	M	56	OCULAR THERAPEUTIX, INC.	6 years
Amar Sawhney	M	-	OCULAR THERAPEUTIX, INC.	2 years

Statistics

Country	Connections	% of total
United States	32	94.12%
Canada	2	5.88%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections